RePORT ⟩ RePORTER

Project Details

TASK V17: DEVELOPMENT OF ASSAYS AND REAGENTS FOR MONKEYPOX VACCINES

Project Number272201800013I-0-759302200004-1

Contact PI/Project LeaderRUDGE, THOMAS

Awardee OrganizationBATTELLE CENTERS/PUB HLTH RES & EVALUATN

Description

Abstract Text

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.

Public Health Relevance Statement

Data not available.

NIH Spending Category

BiodefenseBiotechnologyEmerging Infectious DiseasesImmunizationInfectious DiseasesOrphan DrugPreventionRare DiseasesSmall PoxVaccine Related

Project Terms

BiologicalBiological ProductsBioterrorismCommunicable DiseasesContractsDevelopmentEmerging Communicable DiseasesFeasibility StudiesInvestigational New Drug ApplicationLicensingMonkeypoxPoxviridaeReagentServicesVaccinesassay developmentevaluation/testingnovel vaccinesproduct developmenttesting servicesvaccine candidatevaccine development

Details

Contact PI/ Project Leader

Name

RUDGE, THOMAS

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

BATTELLE CENTERS/PUB HLTH RES & EVALUATN

City

COLUMBUS

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Research Institutes

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2022

Award Notice Date

Administering Institutes or Centers

National Institute of Allergy and Infectious Diseases

CFDA Code

DUNS Number

007901598

UEI

F125YU6SWK59

C38HLCBMXG54

FG8QB99NF8K3

GHX2B85PDD27

JV6TBSUWW5N5

JXC5QLN4G6L7

K123X6KCDST9

PSM2KUYFMFJ6

QC9EXJPLGF94

UYJNSX6G9613

UZ94YTYVM7M5

YPNULMCFTKJ3

Z1J4ADJ18R24

ZK2NCUPM4YN1

Project Start Date

01-September-2022

Project End Date

31-August-2023

Budget Start Date

Budget End Date

Project Funding Information for 2022

Total Funding

$1,045,131

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2022	National Institute of Allergy and Infectious Diseases	$1,045,131

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$1,045,131	Biotechnology; Emerging Infectious Diseases; Immunization; Infectious Diseases; Orphan Drug; Prevention; Rare Diseases; Small Pox; Vaccine Related

Sub Projects

No Sub Projects information available for 272201800013I-0-759302200004-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 272201800013I-0-759302200004-1

Patents

No Patents information available for 272201800013I-0-759302200004-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 272201800013I-0-759302200004-1

Clinical Studies

No Clinical Studies information available for 272201800013I-0-759302200004-1

News and More

Section Menu